(-0.54%) 5 079.75 points
(-0.37%) 38 535 points
(-0.85%) 17 514 points
(-0.11%) $82.72
(-0.30%) $1.648
(-0.07%) $2 336.80
(0.09%) $27.37
(0.12%) $916.90
(-0.24%) $0.932
(-0.28%) $10.95
(-0.40%) $0.799
(-0.10%) $92.23
Live Chart Being Loaded With Signals
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs...
Stats | |
---|---|
Today's Volume | 1 579.00 |
Average Volume | 8 816.00 |
Market Cap | 25.29M |
EPS | $0 ( 2024-03-07 ) |
Next earnings date | ( $-2.88 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.640 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Wills Robert James | Buy | 3 086 | Common Stock |
2024-03-28 | Wills Robert James | Buy | 6 914 | Common Stock |
2024-02-23 | Hale David F | Buy | 266 | Common Stock |
2024-02-23 | Hale David F | Buy | 714 | Common Stock |
2024-02-23 | Wills Robert James | Sell | 980 | Common Stock |
INSIDER POWER |
---|
19.18 |
Last 100 transactions |
Buy: 5 802 851 | Sell: 3 918 128 |
Oncternal Therapeutics Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oncternal Therapeutics Financials
Annual | 2023 |
Revenue: | $785 000 |
Gross Profit: | $-28.97M (-3 690.19 %) |
EPS: | $-13.43 |
Q4 | 2023 |
Revenue: | $297 000 |
Gross Profit: | $-6.37M (-2 145.79 %) |
EPS: | $-3.11 |
Q3 | 2023 |
Revenue: | $179 000 |
Gross Profit: | $104 000 (58.10 %) |
EPS: | $-3.35 |
Q2 | 2023 |
Revenue: | $106 000 |
Gross Profit: | $69 000.00 (65.09 %) |
EPS: | $-3.05 |
Financial Reports:
No articles found.
Oncternal Therapeutics
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators